Capitol 982x327px

2015 ACKC
Campaign for
Research Funding

Annual campaign to get a
$15 million appropriation
for kidney cancer research

Take one minute and ask your elected officials
for their support via our Votervoice page →

Holding Hand 982x327px

Patient Guides:
Taking Charge of
Kidney Cancer

ACKC’s online pamphlets
inform and empower patients
and their caregivers

View the guides →

Researcher A 982x327px

Support ACKC

ACKC is the only major
kidney cancer grassroots
lobbying organization
raising money that goes
predominantly to fund
kidney cancer research

Donate now →

Slide background

Stay Connected

Join ACKC’s online
community of survivors,
caregivers, family and
friends by liking us
on Facebook…we’re
13,005 members strong!

ACKC on Facebook →

ACKC Point of View

  • The Cost of Cancer Medication

    Why are cancer drug prices skyrocketing? What can be done to rein in costs when drug companies are a “corporate monopoly” with the highest profits of any industry? The patient power of grass-roots groups such as ACKC may hold the solution, says Hagop Kantarjian, M.D., a leader in the in the fight to lower drug costs. Full article coming soon…

News

  • Recent Advances in Kidney Cancer Research and Treatment

    May 1, 2015

    Dr. W. Marston Linehan, Chief of Urologic Oncology at the National Cancer Institute (NCI) recently spoke to the advocacy group that gathered in Washington, DC, for ACKC’s annual Campaign for Research Funding. Dr. Linehan spoke to the group in layman’s terms regarding the recent advances in kidney cancer research (see video below). He described the strong sense of hope and excitement for major breakthroughs that may be coming as researchers are making significant progress regarding… More →

  • Concerts to Conquer Kidney Cancer

    April 27, 2015

    Join us for Concerts to Conquer Kidney Cancer — 2015 Tour. The concerts, two-piano performances by Brenda Casey and Pat Todd, are fundraisers to raise awareness of kidney cancer, advocate for increased research funding, and benefit ACKC. View the schedule and program. Meet the performers.

  • Nivolumab Approved for Another Cancer

    March 7, 2015

    On March 4, 2015, the FDA approved the Bristo-Myers Squibb (BMS) immunotherapy drug nivolumab (Opdivo) for use in non-small cell lung cancer (NSCLC) patients for whom other drugs have failed. The approval was based on interim results in a Phase III trial testing nivolumab, at 3 mg/kg, against docetaxel, a chemotherapy drug. Nivolumb was found to have extended overall survival (OS) by three months over docetaxel, giving patients on nivolumab a median OS of 9.2… More →

  • Exposome

    February 16, 2015

    A recent segment on NPR, segment, reported about a study, involving tens of thousands of participants over a 50-year period, by Dr. Barbara Cohn from UC Berkeley looking into the effect of environmental factors on the development of breast cancer in mothers and their children. Dr. Cohn plans to map out what’s called the “exposome” (see exposome), which is a map of the exposure of an individual over his or her lifetime to various environmental and… More →

  • Rebound and Resistance in Targeted Therapies

    December 24, 2014

    John Ebos of Roswell Park Cancer Institute was granted a Career Development Award by the Congressionally Directed Medical Research Programs of the Department of Defense (DoD) to study, using a pre-clinical model, rebound and resistance to targeted therapies in RCC. This two-year grant was funded at $602,996 in Fiscal Year 2013 (the latest award year). This project is designed to answer a number of important questions, in regard to targeted therapy, that have not been… More →